Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia, lack of oxygen to the heart muscle. However, the success of returning blood supply is limited by an obstruction known as intramyocardial hemorrhage. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling (sudden change of size), risk of rapid, electric impulses, known as fatal arrhythmia. Recent imaging techniques have improved restoration, however, the association between MRI contrasts and restoration is highly unclear, and lacks specificity to the Institute for Medical Humanities (IMH). Improved imaging of IMH and accurate knowledge may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for sudden change of size. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic ability of tissues and can target tissue iron. The investigators hypothesize that MRI imaging of myocardial magnetic abilities can map heart bleeding. The investigators will perform a study in patients after restoration to for validation, compare the methods with conventional MR contrasts, and develop MR methods for imaging humans.
This study began on April 1, 2018 and is estimated to be completed by March 31, 2023. It is a cohort, observational study with an estimated 70 participants. The clinical trial has a follow-up session 5 years later.
- All sexes, between the ages of 18 and 80
- Patients must be able to read and understand English
- Participants must sign the informed consent form
- Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
- ST elevation detected on ECG
- Contraindications to cardiac MRI, including claustrophobia
- Advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
- Presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
- Personal or family history of hypertrophic cardiomyopathy
- Inability to provide informed consent
- History of seizure disorder
You may participate in this study at the University of Pennsylvania in Philadelphia, Pennsylvania, United States, 19104. If you have any questions or concerns please contact Walter R Witschey, PhD at 215-662-2310 or at firstname.lastname@example.org.
This study is sponsored by the University of Pennsylvania.
Clinical TrialsView All
Testing a Community Intervention to Increase Aspirin Use
Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men,…
Impact of Daylight on Patients With Acute Myocardial Infarction
Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is…
CLEAR SYNERGY Neutrophil Substudy
CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and…
Evaluating Vitamin D Normalization on Cardiovascular-Related Events
This study evaluates whether achieving 25-hydroxyvitamin D, or 25[OH] Vit D (what vitamin D is converted into…
The Impact of Early Follow-up on Readmission Rates in AMI Patients
This study aims to conduct the first randomized, prospective trial to better clear up the association between early…
Testosterone Replacement and Exercise Capacity in Hypogonadal Men
This study examines the effect of testosterone replacement on the ability to exercise for men with functional…